Focused on Growth and Innovation

“Patients are at the heart of what we do”

Baader Helvea - Virtual Swiss Equities Conference
David Veitch, CEO & Adesh Kaul, CFO
January 13, 2021

At a glance

- Well funded, commercial-stage biopharmaceutical company with significantly growing cash flows from commercialized products
- Focused in the areas of oncology and infectious diseases
- Potential for sustainable growth and value creation based on commercialized brands and an innovative pipeline
- Experienced people with the proven expertise to take compounds from research to market
- Two revenue generating hospital anti-infective brands, Cresemba® and Zevtera® and two clinical oncology drug candidates
- Recognized ability to establish and manage partnerships in both the development and commercial phase, providing access to international markets
- Listed on SIX Swiss Stock Exchange, SIX: BSLN
- Based in life sciences hub, Basel, Switzerland

Potential for sustainable growth and value creation based on commercialized brands and innovative pipeline



Global coverage — Cresemba®



The company we keep — established strong partnerships

License partners

Pfizer
Europe (excl. Nordics), China Asia-Pacific, Russia, Turkey ans Israel (Cresemba®)

astellas
U.S. (Cresemba®)

AsahiKASEI
Japan (Cresemba®)

CR Gosun
China (Zevtera®)

Distribution partners

correvio
Europe (excl. Nordics), Israel (Zevtera®)

hikma.
MENA region (Cresemba® and Zevtera®)

GBT Grupo Biotoscana
LatAm (Cresemba® and Zevtera®)

UNIMEDIC PHARMA
Nordics (Cresemba® and Zevtera®)

AVIR PHARMA
Canada (Cresemba® and Zevtera®)



Antifungal

Cresemba® (isavuconazole)

Invasive mold infections

The market — Invasive fungal infections

- Severe, potentially life-threatening infections mainly affecting immunocompromised patients
- An important cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens
- Rising number of immunocompromised patients
  (cancer and transplantations) driving therapeutic demand
- Mucorales infections on the rise – doubled from 2000 to 2013
- Limitations of current therapies (spectrum of activity, toxicity, effective plasma levels) drive the need for new agents



**Kullberg/Arendrup *N Engl J Med* 2015, Baddley *Clin Infect Dis* 2010, Roden *Clin Infect Dis* 2005, Greenberg *Curr Opin Infect Dis* 2004

Cresemba continues strong in-market sales uptake

USD 244 mn "in-market" sales in the 12 months to September 2020



LCD: USD corrected for currency fluctuations; MAT: Moving annual total; Source: IQVIA, September 2020

Sales of best-in-class antifungals* by product

USD 3.1 bn sales (MAT Q3 2020)

- Potential to increase Cresemba® (isavuconazole) market share
  - Anticipate to be launched in 60 countries by end-2021
  - Exclusivity through 2027 in the U.S. and potential pediatric exclusivity extension to 2027 (from 2025) in the EU



* Best-in-class antifungals: isavuconazole, posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations;
Source: IQVIA, September 2020

Antibacterial

Zevtera® / Mabelio® (ceftobiprole)

Severe bacterial infections

Zevtera® — An introduction

- Broad-spectrum anti-MRSA cephalosporin (including Gram-negative bacteria)
- Rapid bactericidal activity
- Potential to replace antibiotic combinations
- Early improvement in HAP, particularly in patients with MRSA, and CAP, including high-risk patients
- Cephalosporin class safety profile
- Marketed in selected countries in Europe, Latin America and the MENA-region as well as in Canada

Approved in major European countries & several non-European countries for both hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and community-acquired pneumonia (CAP). Not approved in the U.S.

MENA: Middle East and North Africa

The hospital anti-MRSA antibiotic market — A USD 2.8 bn market* with the U.S. being the most important region

Daptomycin sales by region (2015, before LOE)



Ceftaroline sales by region (MAT Q3 2020)



* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, oritavancin, and tedizolid

MRSA: Methicillin-resistant *Staphylococcus aureus*; LOE: Loss of exclusivity; ROW: Rest of world
MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations; Source: IQVIA, September 2020

Strategy for accessing the U.S. market

- Two cross-supportive phase 3 studies under FDA Special Protocol Assessment (SPA)

1. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)[1] successfully completed

TARGET
ABSSSI Study

2. *Staphylococcus aureus* bacteremia (SAB)[2] ongoing, topline results from phase 3 study expected in H1 2022

ERADICATE
SAB Study

- Phase 3 program largely funded by BARDA (up to USD ~130 mn, ~70% of total program costs)

BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY
BARDA

- Qualified Infectious Disease Product (QIDP) designation extends U.S. market exclusivity to 10 years from approval

[1] Overcash JS et al. ECCMID 2020, abstract 1594. (NCT03137173)
[2] Hamed K et al. Future Microbiol. 2020;15:35-48. (NCT03138733)

Oncology

Derazantinib

FGFR-driven tumors

Targeting FGFR-driven tumors as single agent and in combination with immunotherapy

- Small molecule, oral inhibitor of FGFR family of kinases
- Development strategy focused on achieving differentiation by leveraging unique properties of derazantinib
  - Kinase inhibition profile: exploring therapeutic potential of additional targets of derazantinib such as CSF1R and VEGFR2 kinase
  - Safety profile: exploring relevance for potential combination therapies
- Three clinical studies ongoing
  - FIDES-01 (Ph 2) in intrahepatic cholangiocarcinoma (iCCA)
  - FIDES-02 (Ph 1/2) in urothelial cancer
  - FIDES-03 (Ph 1/2) in gastric cancer



Sources: Helsten et al., Clin Cancer Res 2016 (22), 257-267; FGFR2 fusions in iCCA: Graham et al. Hum Pathol 2014 (45), 1630-1638; Jain et al. JCO Precis Oncol 2018 (2) 1-12

Registrational phase 2 study in iCCA (FIDES-01)[1]

Cohort 1: Patients with FGFR2 gene-fusion expressing iCCA (2nd line)

- Encouraging interim results, consistent with earlier phase 1/2 data[2]
  - 21% ORR with six confirmed partial responses from 29 evaluable patients, 83% disease control rate
  - Manageable safety profile with low incidence of nail toxicity, retinal events, hand-foot syndrome and stomatitis
- Topline results expected Q1 2021

Cohort 2: Patients with FGFR2 gene mutations or amplifications

- Define the full therapeutic potential in iCCA with potential for differentiation
- Encouraging interim results - progression-free survival consistent with outcome in patients with FGFR2 gene-fusions[3]
  - Pooled data from 23 patients treated in clinical studies and from the early access and compassionate use programs
  - 7.2 months median progression free survival and 8.2 months median duration of treatment
- Interim results expected H1 2021

[1] NCT03230318
[2]Droz Dit Busset et al. Annals of Oncology (2019) 30 (suppl_5): abstract 3879 (NCT01752920)
[3]Droz Dit Busset et al. Annals of Oncology (2020) 31 (suppl_5): abstract 45P (NCT01752920, NCT03230318)

Oncology

Lisavanbulin (BAL101553)

Glioblastoma
and other solid tumors

Novel tumor checkpoint controller crossing the blood-brain barrier

- Novel compound inducing tumor cell death through spindle assembly checkpoint activation
- Targeting diverse tumor types resistant to standard therapeutic approaches
- Flexible dosing potential, including daily oral dosing
- Comprehensive biomarker program to optimize patient selection
- Crosses the blood-brain barrier with potent activity in brain tumor models alone and in combination
- Biomarker-driven phase 2 study in patients with recurrent glioblastoma (GBM) using EB1-positivity as patient selection criterion ongoing



* Lisavanbulin (BAL101553) is a prodrug of BAL27862

Financials

Financial guidance

In CHF mn	FY 2019 actuals	FY 2020 guidance	FY 2020e*
Total revenue	134.4	128–138	128
thereof: Contributions Cresemba® & Zevtera®			
non-deferred	68.7	77–87	78
deferred	45.6	33	34
Operating loss	17.2	5–15	N/A
Cash and investments	161.0	150	167

Strong increase in non-deferred revenue contributions Y-o-Y, CHF mn



* The audited full financial statements as well as the annual report 2020 will be published on February 16, 2021. The final audited revenue for 2020 and the cash position as of year-end 2020 may differ from the preliminary reported numbers.

Milestones & Outlook 2021 / 2022

Cresemba® & Zevtera® — Increasing cash flows
By the end of 2021, Cresemba to be on the market in 60 countries

		H1 2021	H2 2021	H1 2022	H2 2022
Isavuconazole		✓ Complete patient enrolment in phase 3 study in Japan	Topline results from phase 3 study in Japan		
Ceftobiprole			Complete patient enrolment in SAB phase 3 study	Topline results from SAB phase 3 study	
Derazantinib	**FIDES-01 (iCCA)**	Topline results (FGFR2 fusions)			
		Interim results (other FGFR2 gene aberrations)		Topline results (other FGFR2 gene aberrations)	
	FIDES-02 (urothelial cancer)	Interim results in derazantinib monotherapy	Interim results in combination therapy with atezolizumab		Topline results in combination therapy with atezolizumab
	FIDES-03 (gastric cancer)		Interim results in monotherapy and recommended phase 2 dose with ramucirumab and paclitaxel		Interim results in combination with ramucirumab and paclitaxel
Lisavanbulin (Oral)			Interim results from phase 2 biomarker-driven GBM study	Topline results from phase 2 biomarker-driven GBM study	
			Recommended phase 2 dose in phase 1 study in newly-diagnosed GBM in combination with radiotherapy		

Appendix

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law. Derazantinib and its uses are investigational and have not been approved by a regulatory authority for any use. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in nonclinical/preclinical studies to humans is currently being evaluated.

Focused on Growth and Innovation

Grenzacherstrasse 487
PO Box
4005 Basel
Switzerland

investor_relations@basilea.com
www.basilea.com